June 9, 2022 03:18 PM EDTUpdated June 23, 02:20 PM
Financing
Deals

#BIO22: The bear mar­ket may be maul­ing biotech stocks, but the fun­da­men­tals still look good to re­al es­tate de­vel­op­ers

Sarah Cohen

Contributor

The bear mar­ket that has cut the val­u­a­tions of biotech com­pa­nies has not yet af­fect­ed re­al es­tate de­vel­op­ment in life sci­ences, which con­tin­ues to ex­pe­ri­ence …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times